Investors & Media
Aileron Therapeutics is a clinical-stage biopharmaceutical company that is discovering and developing novel medicines to improve the outcomes and the quality of life of cancer patients by targeting high-value and historically undruggable targets using our proprietary platform of stabilized cell-permeating peptides. Our lead product candidate, ALRN-6924, is a cell-permeating peptide that mimics the p53 tumor suppressor protein to disrupt p53’s interactions with its endogenous inhibitors, MDMX and MDM2. Our focus at Aileron is the clinical development of ALRN-6924 to protect cancer patients against chemotherapy-induced toxicities, a novel concept we call “chemoprotection."More >>
|Data as of
Data Provided by Refinitiv. Minimum 15 minutes delayed.